Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis

REFERENCES

• Albanell, J., and Baselga J.. 2001. Unraveling resistance to trastuzumab (herceptin): insulin-like growth factor-I receptor, a new suspect. J. Natl. Cancer Inst. 93:1830–1832.
   PubMedGoogle Scholar
• Araki, E., Lipes M. A., Patti M. E., Bruning J. C., Haag III B., Johnson R. S., and Kahn C. R.. 1994. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186–190.
   PubMed Web of Science ®Google Scholar
• Bachelder, R. E., Marchetti A., Falcioni R., Soddu S., and Mercurio A. M.. 1999. Activation of p53 function in carcinoma cells by the α6β4 integrin. J. Biol. Chem. 274:20733–20737.
   PubMedGoogle Scholar
• Boudreau, N., and Bissell M. J.. 1998. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 10:640–646.
   PubMed Web of Science ®Google Scholar
• Bruning, J. C., Winnay J., Cheatham B., and Kahn C. R.. 1997. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol. Cell. Biol. 17:1513–1521.
   PubMed Web of Science ®Google Scholar
• Cantley, L. C. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655–1657.
   PubMed Web of Science ®Google Scholar
• Conneely, O. M., Jericevic B. M., and Lydon J. P.. 2003. Progesterone receptors in mammary gland development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 8:205–214.
   Google Scholar
• Cui, X., Lazard Z., Zhang P., Hopp T. A., and Lee A. V.. 2003. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Oncogene 22:6937–6941.
   PubMedGoogle Scholar
• Dunn, S. E., Ehrlich M., Sharp N. J., Reiss K., Solomon G., Hawkins R., Baserga R., and Barrett J. C.. 1998. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58:3353–3361.
   PubMed Web of Science ®Google Scholar
• Farrelly, N., Lee Y.-J., Oliver J., Dive C., and Streuli C. H.. 1999. Extracellular matrix regulates apoptosis in mammary epithelium through a control on insulin signaling. J. Cell Biol. 144:1337–1347.
   PubMedGoogle Scholar
• Fasshauer, M., Klein J., Ueki K., Kriauciunas K. M., Benito M., White M. F., and Kahn C. R.. 2000. Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J. Biol. Chem. 275:25494–25501.
   PubMed Web of Science ®Google Scholar
• Guvakova, M. A., and Surmacz E.. 1997. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 57:2606–2610.
   PubMed Web of Science ®Google Scholar
• Guy, C. T., Cardiff R. D., and Muller W. J.. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12:954–961.
   PubMed Web of Science ®Google Scholar
• Hadsell, D. L., and Bonnette S. G.. 2000. IGF and insulin action in the mammary gland: lessons from transgenic and knockout models. J. Mammary Gland Biol. Neoplasia 5:19–30.
   Google Scholar
• Hanahan, D., and Weinberg R. A.. 2000. The hallmarks of cancer. Cell 100:57–70.
   PubMed Web of Science ®Google Scholar
• Harrington, L. S., Findlay G. M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N. R., Cheng S., Shepherd P. R., Gout I., Downes C. P., and Lamb R. F.. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213–223.
   PubMed Web of Science ®Google Scholar
• Hellawell, G. O., Turner G. D., Davies D. R., Poulsom R., Brewster S. F., and Macaulay V. M.. 2002. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2942–2950.
   PubMed Web of Science ®Google Scholar
• Jackson, J. G., White M. F., and Yee D.. 1998. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells. J. Biol. Chem. 273:9994–10003.
   PubMed Web of Science ®Google Scholar
• Jackson, J. G., Zhang X., Yoneda T., and Yee D.. 2001. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 20:7318–7325.
   PubMed Web of Science ®Google Scholar
• Lavan, B. E., Fantin V. R., Chang E. T., Lane W. S., Keller S. R., and Lienhard G. E.. 1997. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J. Biol. Chem. 272:21403–21407.
   PubMed Web of Science ®Google Scholar
• Lavan, B. E., Lane W. S., and Lienhard G. E.. 1997. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J. Biol. Chem. 272:11439–11443.
   PubMed Web of Science ®Google Scholar
• Lee, A. V., Jackson J. G., Gooch J. L., Hilsenbeck S. G., Coronado-Heinsohn E., Osborne C. K., and Yee D.. 1999. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 13:787–796.
   PubMed Web of Science ®Google Scholar
• Lee, A. V., Zhang P., Ivanova M., Bonnette S., Oesterreich S., Rosen J. M., Grimm S., Hovey R. C., Vonderhaar B. K., Kahn C. R., Torres D., George J., Mohsin S., Allred D. C., and Hadsell D. L.. 2003. Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. Endocrinology 144:2683–2694.
   PubMedGoogle Scholar
• Lee, Y. J., and Streuli C. H.. 1999. Extracellular matrix selectively modulates the response of mammary epithelial cells to different soluble signaling ligands. J. Biol. Chem. 274:22401–22408.
   PubMed Web of Science ®Google Scholar
• LeRoith, D., and Roberts C. T., Jr. 2003. The insulin-like growth factor system and cancer. Cancer Lett. 195:127–137.
   PubMed Web of Science ®Google Scholar
• Lin, E. Y., Jones J. G., Li P., Zhu L., Whitney K. D., Muller W. J., and Pollard J. W.. 2003. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163:2113–2126.
   PubMed Web of Science ®Google Scholar
• Lin, Y., Tamakoshi A., Kikuchi S., Yagyu K., Obata Y., Ishibashi T., Kawamura T., Inaba Y., Kurosawa M., Motohashi Y., and Ohno Y.. 2004. Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death. Int. J. Cancer 110:584–588.
   PubMedGoogle Scholar
• Lu, Y., Zi X., Zhao Y., Mascarenhas D., and Pollak M.. 2001. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin). J. Natl. Cancer Inst. 93:1852–1857.
   PubMed Web of Science ®Google Scholar
• Mercurio, A. M., Rabinovitz I., and Shaw L. M.. 2001. The alpha 6 beta 4 integrin and epithelial cell migration. Curr. Opin. Cell Biol. 13:541–545.
   PubMed Web of Science ®Google Scholar
• Nolan, M. K., Jankowska L., Prisco M., Xu S., Guvakova M. A., and Surmacz E.. 1997. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int. J. Cancer. 72:828–834.
   PubMed Web of Science ®Google Scholar
• Pan, D., Dong J., Zhang Y., and Gao X.. 2004. Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol. 14:78–85.
   PubMed Web of Science ®Google Scholar
• Resnik, J. L., Reichart D. B., Huey K., Webster N. J., and Seely B. L.. 1998. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 58:1159–1164.
   PubMed Web of Science ®Google Scholar
• Rocha, R. L., Hilsenbeck S. G., Jackson J. G., VanDenBerg C. L., Weng C., Lee A. V., and Yee D.. 1997. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 3:103–109.
   PubMed Web of Science ®Google Scholar
• Sachdev, D., and Yee D.. 2001. The IGF system and breast cancer. Endocr. Relat. Cancer 8:197–209.
   PubMed Web of Science ®Google Scholar
• Salerno, M., Sisci D., Mauro L., Guvakova M. A., Ando S., and Surmacz E.. 1999. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int. J. Cancer. 81:299–304.
   PubMed Web of Science ®Google Scholar
• Sandhu, M. S., Dunger D. B., and Giovannucci E. L.. 2002. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst. 94:972–980.
   PubMed Web of Science ®Google Scholar
• Schnarr, B., Strunz K., Ohsam J., Benner A., Wacker J., and Mayer D.. 2000. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int. J. Cancer 89:506–513.
   PubMed Web of Science ®Google Scholar
• Schubert, M., Brazil D. P., Burks D. J., Kushner J. A., Ye J., Flint C. L., Farhang-Fallah J., Dikkes P., Warot X. M., Rio C., Corfas G., and White M. F.. 2003. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 23:7084–7092.
   PubMed Web of Science ®Google Scholar
• Senger, D. R., Claffey K. P., Benes J. E., Perruzzi C. A., Sergiou A. P., and Detmar M.. 1997. Angiogenesis promoted by vascular endothelial growth factor: regulation through α1β1 and α2β1 integrins. Proc. Natl. Acad. Sci. USA 94:13612–13617.
   PubMed Web of Science ®Google Scholar
• Shaw, L. M. 2001. Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the α6β4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion. Mol. Cell. Biol. 21:5082–5093.
   PubMed Web of Science ®Google Scholar
• Shaw, L. M. 1999. Integrin function in breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 4:367–376.
   Google Scholar
• Shaw, L. M., Chao C., Wewer U. M., and Mercurio A. M.. 1996. Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor. Cancer Res. 56:959–963.
   PubMed Web of Science ®Google Scholar
• Shaw, L. M., Rabinovitz I., Wang H. H. F., Toker A., and Mercurio A. M.. 1997. Activation of phosphoinositide 3-OH kinase by the alpha-6-beta-4 integrin promotes carcinoma invasion. Cell 91:949–960.
   PubMed Web of Science ®Google Scholar
• Sheikh, M. S., Garcia M., Pujol P., Fontana J. A., and Rochefort H.. 1994. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invasion Metastasis 14:329–336.
   PubMedGoogle Scholar
• Sommer, S., and Fuqua S. A.. 2001. Estrogen receptor and breast cancer. Semin. Cancer Biol. 11:339–352.
   PubMed Web of Science ®Google Scholar
• Spicer, A. P., Rowse G. J., Lidner T. K., and Gendler S. J.. 1995. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem. 270:30093–30101.
   PubMed Web of Science ®Google Scholar
• Sutherland, R. L., and Musgrove E. A.. 2004. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia 9:95–104.
   Google Scholar
• Tee, A. R., Fingar D. C., Manning B. D., Kwiatkowski D. J., Cantley L. C., and Blenis J.. 2002. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA 99:13571–13576.
   PubMed Web of Science ®Google Scholar
• Turner, B. C., Haffty B. G., Narayanan L., Yuan J., Havre P. A., Gumbs A. A., Kaplan L., Burgaud J. L., Carter D., Baserga R., and Glazer P. M.. 1997. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57:3079–3083.
   PubMed Web of Science ®Google Scholar
• Vassen, L., Wegrzyn W., and Klein-Hitpass L.. 1999. Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene. Mol Endocrinol. 13:485–494.
   PubMedGoogle Scholar
• Vella, V., Sciacca L., Pandini G., Mineo R., Squatrito S., Vigneri R., and Belfiore A.. 2001. The IGF system in thyroid cancer: new concepts. Mol. Pathol. 54:121–124.
   PubMedGoogle Scholar
• White, M. F. 2002. IRS proteins and the common path to diabetes. Am. J. Physiol. Endocrinol. Metab. 283:E413–E422.
   PubMed Web of Science ®Google Scholar
• Withers, D. J., Burks D. J., Towery H. H., Altamuro S. L., Flint C. L., and White M. F.. 1999. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 23:32–40.
   PubMed Web of Science ®Google Scholar
• Withers, D. J., Gutierrez J. S., Towery H., Burks D. J., Ren J. M., Previs S., Zhang Y., Bernal D., Pons S., Shulman G. I., Bonner-Weir S., and White M. F.. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900–904.
   PubMed Web of Science ®Google Scholar
• Zhang, X., Kamaraju S., Hakuno F., Kabuta T., Takahashi S., Sachdev D., and Yee D.. 2004. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res. Treat. 83:161–170.
   Google Scholar